Adjuvant CapitalRA Capital ManagementJanus Henderson Investors
Description
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
Who to call at Curevo, and when
A new round usually means Curevo is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Curevo raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Curevo, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Curevo
Location
Bothell, Washington, United States
About
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curevo raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BothellBiotechnologyHealthcareMobileSportsPlatforms